Literature DB >> 11861388

The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity.

Elina Azenshtein1, Galia Luboshits, Sima Shina, Eran Neumark, David Shahbazian, Miguel Weil, Nely Wigler, Iafa Keydar, Adit Ben-Baruch.   

Abstract

Breast cancer progression may be affected by various cellular components expressed by the tumor cells and/or by microenvironmental factors. Many studies report the correlation between breast cancer progression and monocyte infiltration into the tumor site. We have identified recently the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES), a major monocyte chemoattractant expressed by breast tumor cells, as a potential contributor to breast cancer progression. In the present study, analysis of the regulation of RANTES expression demonstrates that the expression of RANTES in breast tumor cells is elevated significantly and in a synergistic manner by IFN-gamma and tumor necrosis factor-alpha. Identification of the mechanisms by which RANTES may contribute to breast cancer progression included the analysis of the potential ability of RANTES to act in paracrine and indirect mechanisms, as well as directly on the tumor cells, to promote disease progression. Our results suggest that breast tumor cell-derived RANTES may promote breast cancer progression by its partial contribution to monocyte migration into breast tumor sites. Moreover, RANTES promotes the expression of matrix metalloproteinase (MMP) 9 by THP-1 monocytic cells and elevates vascularity in chick chorioallantoic membrane assays. Tumor necrosis factor-alpha, a major monocyte-derived cytokine, was found to promote the expression of MMP9 and MMP2 by MCF-7 and T47D breast adenocarcinoma cells, respectively, and to induce the de novo expression of an additional proteolytic enzyme by T47D cells, presumably MMP9. The possibility that RANTES may act directly on breast tumor cells was supported by detection of the expression of the CCR5 RANTES receptor in biopsy sections of breast cancer patients and by the ability of RANTES to promote the expression of MMP9 by MCF-7 cells. In all, our study suggests that the expression of RANTES by breast tumor cells results not only in monocyte migration to the tumor site but also in protumorigenic activities of RANTES and of proinflammatory cytokines that may facilitate metastasis formation and contribute to disease progression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861388

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  112 in total

1.  Tumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway.

Authors:  Xuesong Qian; Jidong Zhang; Jianguo Liu
Journal:  J Biol Chem       Date:  2010-11-19       Impact factor: 5.157

2.  Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production.

Authors:  Vera Levina; Adele M Marrangoni; Richard DeMarco; Elieser Gorelik; Anna E Lokshin
Journal:  Exp Cell Res       Date:  2008-01-16       Impact factor: 3.905

3.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

4.  Absence of multiple atypical chemokine binders (ACBs) and the presence of VEGF and MMP-9 predict axillary lymph node metastasis in early breast carcinomas.

Authors:  Xiao-Hua Zeng; Zhou-Luo Ou; Ke-Da Yu; Lan-Yun Feng; Wen-Jing Yin; Jing Li; Zhen-Zhou Shen; Zhi-Min Shao
Journal:  Med Oncol       Date:  2014-08-06       Impact factor: 3.064

Review 5.  Chemokines: novel targets for breast cancer metastasis.

Authors:  Simi Ali; Gwendal Lazennec
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 6.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

7.  A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.

Authors:  Paolo Monti; Federica Marchesi; Michele Reni; Alessia Mercalli; Valeria Sordi; Alessandro Zerbi; Giampaolo Balzano; Valerio Di Carlo; Paola Allavena; Lorenzo Piemonti
Journal:  Virchows Arch       Date:  2004-07-17       Impact factor: 4.064

8.  c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion.

Authors:  Xuanmao Jiao; Sanjay Katiyar; Nicole E Willmarth; Manran Liu; Xiaojing Ma; Neal Flomenberg; Michael P Lisanti; Richard G Pestell
Journal:  J Biol Chem       Date:  2010-01-06       Impact factor: 5.157

Review 9.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

10.  LYR71, a derivative of trimeric resveratrol, inhibits tumorigenesis by blocking STAT3-mediated matrix metalloproteinase 9 expression.

Authors:  Ja Eun Kim; Hong Sook Kim; Yong Jae Shin; Chang Seok Lee; Cheolhee Won; Sin Ae Lee; Jung Weon Lee; Youngsoo Kim; Jae Seung Kang; Sang Kyu Ye; Myung Hee Chung
Journal:  Exp Mol Med       Date:  2008-10-31       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.